Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 6/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1861340 | 1.00 | CA1 (0.40) | CA1CA2CA7ATMCTSK | |
| SCHEMBL1861342 | 1.00 | CA1 (0.40) | CA1CA2CA7ATMCTSK | |
| SCHEMBL31695224 | 0.88 | CA1 (0.35) | CA1CA2CA7ATMCTSK | |
| SCHEMBL30732579 | 0.88 | CA1 (0.35) | CA1CA2CA7ATMCTSK | |
| SCHEMBL3613413 | 0.87 | CA1 (0.39) | CA1CA2CA7ATMCTSK | |
| SCHEMBL3613415 | 0.87 | CA1 (0.39) | CA1CA2CA7ATMCTSK | |
| SCHEMBL213446 | 0.86 | TDP1 (0.40) | CA1CA2CA7ATMCTSK | |
| SCHEMBL211028 | 0.86 | CA1 (0.36) | CA1CA2CA7ATMCTSK | |
| SCHEMBL213445 | 0.86 | TDP1 (0.40) | CA1CA2CA7ATMCTSK | |
| SCHEMBL211029 | 0.86 | CA1 (0.36) | CA1CA2CA7ATMCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3413922-B1 | IMPROVED SULFAMIDE LINKERS FOR USE IN BIOCONJUGATES | SYNAFFIX BV (NL) | 2025-12-10 | — | — | EP | disclosed |
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-20 | — | — | US | disclosed |
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION | 2025-11-13 | — | — | US | disclosed |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2025137639-A1 | MIXED SEROTONIN RECEPTOR BINDERS FOR TREATMENT OF PSYCHOTIC DISORDERS | DELIX THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| EP-4531849-A1 | HETEROCYCLIC PAD4 INHIBITORS | CELGENE CORPORATION (US) | 2025-04-09 | — | — | EP | disclosed |
| US-11957763-B2 | Sulfamide linkers for use in bioconjugates | SYNAFFIX B.V. (NL) | 2024-04-16 | — | — | US | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | ELI LILLY AND COMPANY | 2007-09-27 | — | — | US | disclosed |
| US-20070185152-A1 | Inhibitors of akt activity | SMITHKLINE BEECHAM CORPORATION | 2007-08-09 | — | — | US | disclosed |
| WO-2007070865-A2 | PIPERAZINE COMPOUNDS AS AGONISTS OF TRPV4 CHANNEL RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353848-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI1, PADI6 | CA1 3667/4885CA2 4042/4885CA7 2790/4885 |
| US-20080318945-A1 | Novel Compounds | TRPV4, TRPV1, TRPV3 | CA1 3946/4885CA2 520/4885CA7 2877/4885 |
| US-11957763-B2 | Sulfamide linkers for use in bioconjugates | CD22, SPG11, SP1 | CA1 934/4885CA2 2442/4885CA7 1047/4885 |
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CA1 3197/4885CA2 2667/4885CA7 2522/4885 |
| US-20070185152-A1 | Inhibitors of akt activity | AKT1, AKT1S1, AKT2 | CA1 3648/4885CA2 3883/4885CA7 3427/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CA1 3197/4885CA2 2667/4885CA7 2522/4885 |
| US-20070225267-A1 | 3-(2-Acylamino-1-Hydroxyethyl)-Morpholine Derivatives and Their Use as Bace Inhibitors | BACE1, BACE2, APP | CA1 1464/4885CA2 2660/4885CA7 1442/4885 |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | SF3B5, SF3B2, SF3B1 | CA1 4838/4885CA2 4657/4885CA7 4739/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | CA1 855/4885CA2 1677/4885CA7 1209/4885 |
| US-20250346592-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI6, PADI2 | CA1 2957/4885CA2 3840/4885CA7 3010/4885 |
| US-20080293712-A1 | Benzo[C][2,7]Naphtyridine Derivatives, Methods of Making Thereof and Methods of Use Thereof | PDPK1, PDK2, PDK3 | CA1 3315/4885CA2 1620/4885CA7 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.